Eli Lilly slaps down Teva's challenge to Alimta exclusivity

Eli Lilly ($LLY) has fought tooth and nail to protect a patent for its blockbuster cancer drug Alimta, chalking up some victories in the U.S. despite setbacks overseas. Now the company is celebrating a big win as a federal court ruled in its favor, granting Lilly 5 more years of Alimta exclusivity in the U.S. Report